DARA Biosciences Inc

DARA Biosciences — IPO Roadshow (July 2008)

29 slides from DARA Biosciences's IPO roadshow presentation, Jul 9, 2008

  1. Slide 1: Collins Stewart 4th Annual Growth Conference

    Filed Pursuant to Rule 433 Registration No. 333-150150 July 9, 2008 Collins Stewart 4th Annual Growth Conference July 10, 2008 NASDAQ: DARA Confidential 1

  2. Slide 2: Registration Statement; SEC Filings

    Registration Statement; SEC Filings The issuer has filed a registration statement (including a prospectus) with the SEC for a securities offering to which this communication may be deemed to relate. Before you invest in such offering, you should read the prospectus in that registration statement and

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements CERTAIN STATEMENTS IN THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO STATEMENTS, ESTIMATES, ASSUMPTIONS AND PROJECTIONS FOR FUTURE TRENDS AND OF OUR ANTICIPATED FUTURE PERFORMANCE, CONSTITUTE “FORWARD-LOOKING STATEMENTS.” SUCH FORWARD- LOOKING STATEMENTS INVOLVE KNOWN AND UNK

  4. Slide 4: DARA BioSciences unique pharmaceutical product development business model

    DARA BioSciences is executing a unique pharmaceutical product development business model designed to maximize returns, minimize risk and dramatically reduce the revenue generation timeframe Confidential 4

  5. Slide 5: We are…

    We are… Developing drugs that address large market opportunities Product focused with strong patent protection Reducing product development risk Five diverse drug development programs targeting multiple high-value therapies Focused on lower-cost/higher-return stages of development Late Pre-clinical

  6. Slide 6: History

    History Founded by Steve Gorlin in 2002 Funded with $21 million in private equity from three financing rounds between 2003-2006 Completed reverse-merger with Point Therapeutics on 2/12/08 and now trades as DARA BioSciences (NasdaqCM: DARA) $30 million shelf went effective on 4/18/08 with no review C

  7. Slide 7: Corporate Strategy

    Corporate Strategy Produce a revenue stream derived from the licensing and/or sale of drug candidates to large pharmaceutical companies Acquisition, Development and Sale Drug Marketing Discovery Approval Discovery Pre-Clinical IND Phase 1 Phase 2 Phase 3 Research DARA HIGHEST FOCUS HIGHEST RISK $$$

  8. Slide 8: Earlier Phase Deals Yielding Higher Value Terms

    Earlier Phase Deals Yielding Higher Value Terms Change in Cost of Deal Terms 2003 by Clinical Phase of Asset* 2006 400 Value of Phase 1 350 365 and 2 development 300 250 280 300 deals have 200 increased by 75% 150 160 171 190 between 2003 and 100 2006 50 0 Phase I Phase II Phase III *SOURCE: Jones,

  9. Slide 9: Pipeline Portfolio Strategy

    Pipeline Portfolio Strategy Maintain a rolling pipeline of 4 – 6 drug programs Constant scanning for new drug program acquisitions Cut programs quickly as adverse results occur to focus resources on greater value opportunities Balanced risk approach to pipeline creation with multiple drug developmen

  10. Slide 10: Current Pipeline

    Current Pipeline Candidate Selection Lead Proof of Pre-Clinical Indication Drug Identification Principle Development Phase 1 Phase 2a Neuropathic Pain KRN5500 First in Class – No Competition for Drugs of its Type Type 2 Diabetes DB959 Leader in its Class – No Competition in the Clinic Type 2 Diabete

  11. Slide 11: Cancer Neuropathic Pain: KRN5500

    Cancer Neuropathic Pain: KRN5500 Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Active component of KRN5500 has been shown to inhibit nerve cell pain signals Inhibits Excitatory Post-Synaptic Potentials similar to a -opioid agonist and Neurontin

  12. Slide 12: KRN5500 Phase 2 Trials

    KRN5500 Phase 2 Trials Current Phase 2a trial: Assess the safety and alleviation of neuropathic pain in terminally- ill cancer patients Randomized, double-blind, placebo controlled study in 18 patients over 14-week duration Study completion expected in 4Q08 Next Phase 2 trial: Commence open label st

  13. Slide 13: CIPN: An Unexploited Market Opportunity for KRN5500

    CIPN: An Unexploited Market Opportunity for KRN5500 Inadequate current therapies No marketed medicines are approved for use in treating CIPN Variable and minimal benefits with gabapentin, opioids, tricyclic anti-depressants and anti-convulsants Low potential competition Cesamet (synthetic cannabinoi

  14. Slide 14: KRN5500 Non-Clinical Studies

    KRN5500 Non-Clinical Studies Effective in 3 different models of Neuropathic Pain SNI Model Chung Model Bennett Model Ineffective in a model of Regular (nociceptive) Pain CFA Model References: Kobierski, L.A., et.al, Anesth Analg 2003;97:174 –82 Abdi, S., et.al., Anesth Analg 2000;91:955–9 Confidenti

  15. Slide 15: Type 2 Diabetes: DB959 (PPAR Agonist)

    Type 2 Diabetes: DB959 (PPAR Agonist) (delta/gamma) Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Activates genes involved in metabolism of sugars and fats, improving the body’s ability to regulate blood sugar Raises good HDL cholesterol and low

  16. Slide 16: Non-Clinical Studies Suggest Greater Cardiac Safety than Avandia

    Non-Clinical Studies Suggest Greater Cardiac Safety than Avandia ® Avandia ® Dose Cardiac Effect @ 3 times human exposure* 20% increase in Heart Weight in all females @ 42 times human exposure* 28% increase in Heart Weight in all females 32% Increase in Heart Weight in all males Avandia: Toxicology

  17. Slide 17: Non-Clinical Studies Suggest Less Weight Gain than Avandia

    Non-Clinical Studies Suggest Less Weight Gain than Avandia ® Effects of chronic treatment with DB959, rosiglitazone, and muraglitazar on body weight in DIO mice PEG/H2O 15 DB959 @ 100mg/kg * 14 Muraglitizar @ 10mg/kg 13 Rosiglitazone @ 10mg/kg * 12 * * * 11 * * 10 * * 9 * * * * * * 8 * * * 7 * * 6 *

  18. Slide 18: DB959 Non-Clinical Activity

    DB959 Non-Clinical Activity Potentially leading successor to Avandia ® and Actos® (whose combined 2006 sales were > $5.6 billion) Glucose control equal to or better than Avandia Lowers Triglycerides better than Avandia Increases good HDL cholesterol better than Avandia Improves HDL: LDL ratio better

  19. Slide 19: DB959 is not like Avandia and Actos

    DB959 is not like Avandia ® and Actos ® Different structure - different activities (DB959 is not a TZD) Avandia® Actos® Substituted indanyl acetic acid DB959 Treating diabetes in ways that Avandia® and Actos® can’t (correcting altered blood lipids CV Disease) Confidential 19

  20. Slide 20: DB959 Investment and Return

    DB959 Investment and Return 2008 2009 2010 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Phase 2a $15M Phase 1b $13M Phase 1a IND $11M Toxicology $9M GMP Synthesis Safety $7M Pharmacology Potential Liquidity Points Formulation $5M Clinical Trial Supply Mfr. and Stability $3M Confidential 20

  21. Slide 21: DB959: Early Lucrative Exits

    DB959: Early Lucrative Exits 2008 2009 2010 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Phase 2a $15M Phase 1b $13M Phase 1a 06/26/2006 IND Metabolex/JNJ $11M Two Clinical (one Phase 1, one, Phase 2) Toxicology PPAR Modulators for Type 2 Diabetes $9M $508M + Royalties GMP Synthesis 10/28/2004 $7M Safety Plexxikon

  22. Slide 22: Psoriasis: DB200 (Topical)

    Psoriasis: DB200 (Topical) Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Inhibits the proliferation of skin cells by cutting off their energy source - resulting in less flaking of the skin and restoration of normal skin tone Inhibits inflammatio

  23. Slide 23: Projected Future Key Milestones

    Projected Future Key Milestones IND IND IND Phase 1 Submission Submission Submission Completion DB959 DB160 DB900 DB959 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 KRN5500 Second Phase 2a Trial KRN5500 KRN5500 complete Second Initial Phase 2a Trial Phase 2a Trial IND Phase 1 initiation complete Submission Complet

  24. Slide 24: Financial Snapshot at 3/31/08

    Financial Snapshot at 3/31/08 Cash $6.8 million 1Q08 Operating Loss ($2.4) million Shares Outstanding 27.2 million Options & Warrants Outstanding 3.5 million Insider Ownership 16.0% Share Price Range (30-Day)* $1.35- $1.35- - $2.00 Market Capitalization** $40.95 million *Range of closing prices

  25. Slide 25: DARA – Potential for Value Creation

    DARA – Potential for Value Creation Key Assets: 5 therapeutic compounds with strong IP addressing large markets Surgi-Vision: Privately held company targeting Deep Brain Stimulation (DBS), with a strategic relationship with Advanced Bionics, a subsidiary of Boston Scientific. DARA owns 9.7%. MiMedX

  26. Slide 26: Thomas W. D'Alonzo, John Didsbury, Steve Gorlin

    Nationally featured in renowned publications, such as The Wall Street Journal and Fortune Magazine, as an authority in the healthcare industry Founder and Co- Founder of several highly successful biotechnology and pharmaceutical companies Steve Gorlin Chairman of the Board including Medicis Pharmace

  27. Slide 27: David J. Drutz, Haywood Cochrane, Board Directors

    Chairman, Tranzyme, Inc. and Tranzyme Pharma Inc. Director, MethylGene Inc. (TSX:MYG) Former VP, Clinical Development; Daiichi Pharmaceutical Corporation David J. Drutz, M.D. Board Director Former VP, Biological Sciences and VP, Clinical Investigation, Smith Kline & French Laboratories Former Presid

  28. Slide 28: Summary

    Summary Clearly defined business strategy addressing large pharma pipeline gaps Diverse portfolio of programs targeting multi-billion dollar market segments Limited reliance on a single drug candidate or therapeutic category Pursuing both proven and innovative mechanisms Lower risk / lower cost appr

  29. Slide 29: Thank You

    Thank You www.darabiosciences.com Investor inquiries: Dahlia Bailey EVC Group (415) 896-5862 Confidential 29

DARA BioSciences — IPO Roadshow (July 2008) on 6ix